Short description
Neogene Therapeutics is a biotech company providing cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
Description
Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.
Neogene's platform allows for the isolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale.
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Amsterdam, Noord-Holland, The Netherlands, Europe
Founded on
January 1, 2018
Exited on
November 2, 2022
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noway Youcantaccess, Uh Ohhhh, Noway Youcantaccess, Absolutely Noaccess, No Way, Nopepepe, Noaccess, Noway Youcantaccess, Noaccessforu
Sign in for full access
Founders
Carsten Linnemann, Ton Schumacher